AI Article Synopsis
Article Abstract
Axillary metastasis is not a common finding in papillary carcinoma. 18F-FDG can detect foci of metastasis in patients with negative 131I scan. We report a case of a 64-year-old man who had undergone thyroidectomy and 131I ablation due to classic type of papillary carcinoma 14 years ago. Follow-up examination revealed high serum thyroglobulin and negative whole body 131I scan. 18F-FDG PET/CT showed focally increased uptake in right axillary as well as supraclavicular and bilateral cervical lymph nodes. Histopathological examination of the surgically removed lymph nodes confirmed the metastasis of papillary thyroid carcinoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RLU.0b013e318266cce9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Method for Validating PET and SPECT Cameras for Quantitative Clinical Imaging Trials Using Novel Radionuclides.
J Nucl Med
January 2025
Department of Nuclear Medicine, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Our aim is to report methodology that has been developed to calibrate and verify PET and SPECT quantitative image accuracy and quality assurance for use with nonstandard radionuclides, especially with longer half-lives, in clinical imaging trials. Procedures have been developed for quantitative PET and SPECT image calibration for use in clinical trials. The protocol uses a 3-step approach: check quantitative accuracy with a previously calibrated radionuclide in a simple geometry, check the novel trial radionuclide in the same geometry, and check the novel radionuclide in a more challenging, complex geometry (the National Electrical Manufacturers Association [NEMA] NU-2 International Electrotechnical Commission [IEC] image-quality phantom).
View Article and Find Full Text PDF[18F]Tetrafluoroborate: a new NIS PET/CT radiopharmaceutical. An overview focused on differentiated thyroid cancer.
Eur Thyroid J
January 2025
G Treglia, Repubblica e Cantone Ticino Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Background: In relapsing differentiated thyroid cancer (DTC), the in vivo evaluation of natrium-iodine symporter (NIS) expression is pivotal in the therapeutic planning and is achieved by [131/123I]Iodine whole-body scan. However, these approaches have low sensitivity due to the low sensitivity due to the low resolution of SPECT. [18F]Tetrafluoroborate (TFB) has been proposed as a viable alternative, which could outperform [131/123I]Iodine scans owing to the superior PET resolution.
View Article and Find Full Text PDFRetrospective study of post-treatment I SPECT/CT imaging for personalizing therapy of patients with differentiated thyroid cancer.
Folia Med (Plovdiv)
December 2024
Military Medical Academy, Sofia, Bulgaria.
The absence of anatomical landmarks in the whole body scan makes it challenging to precisely localize 131I uptake, which is used to treat patients with differentiated thyroid cancer (DTC). Recently, SPECT/CT studies have been utilized to increase the diagnostic sensitivity and specificity.
View Article and Find Full Text PDFIodine-131 radioembolization boosts the immune activation enhanced by icaritin/resiquimod in hepatocellular carcinoma.
J Control Release
December 2024
Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Center for Biomedical Imaging, Fudan University, Shanghai 200032, China; Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai 200032, China; Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Fudan University, Shanghai 200433, China. Electronic address:
Transarterial radioembolization (TARE) is a recommended locoregional strategy for intermediate hepatocellular carcinoma (HCC), whereas, the effect is insufficient to reverse the immunosuppression tumor microenvironment, and the overall benefits for patients remain to be improved. In this study, a multifunctional microsphere (MS) I-ICT/R848-MS is developed to propose an approach combined with TARE, icaritin (ICT) and immune modulator resiquimod (R848). ICT and iodine-131 (I) radiation can induce immunogenic cell death, which, in combination with R848, will boost dendritic cell (DC) maturation.
View Article and Find Full Text PDFDevelopment and evaluation of a single domain antibody targeting folate receptor alpha for radioligand therapy.
J Nanobiotechnology
December 2024
Precirix, Burg. Etienne Demunterlaan 3, Brussels, Matthias, B-1090, Belgium.
Background: Folate receptor alpha (FRα) overexpression is seen in many cancers. Radioligand therapy (RLT) has emerged as a promising tool to target FRα and has been investigated previously, but further progression was limited due to high kidney retention and, subsequently, toxicity. To circumvent this, we present here the development of a [I]I-GMIB-conjugated anti-human FRα (hFRα) single-domain antibody (sdAb), with intrinsically fast renal clearance and concomitant low kidney retention.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!